- Home
- MIN vs CHRS Comparison
MIN vs CHRS Comparison
Compare MIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | CHRS |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.6M | 291.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MIN | CHRS |
|---|---|---|
| Price | $2.45 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 365.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | 0.08 | ★ 1.43 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $30.81 | ★ $1.13 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.45 | $0.72 |
| 52 Week High | $2.72 | $2.62 |
Technical Indicators
Market Signals| Indicator | MIN | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 26.85 | 38.63 |
| Support Level | N/A | $1.21 |
| Resistance Level | $2.60 | $1.75 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.57 | 1.06 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.